TELA Bio (TELA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$79.9M

Revenue (quarter)

$19.3M

Revenue growth (year over year)

−4.49%

Gross profit (trailing twelve months)

$54.2M

Gross margin

67.81%

Net income (trailing twelve months)

−$41.2M

Net income (quarter)

−$11.3M

Net income growth (year over year)

−13.49%

Net margin

−51.53%

Return on equity

—

EPS (trailing twelve months)

−$0.77

Book value per share

−$0.35

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

126.56%

Payout ratio

—

Dividend yield

—

Company profile

TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

• Is TELA Bio (TELA) profitable?

  No. TELA Bio reported a net loss of $41.2M over the trailing twelve months.

• How much revenue does TELA Bio (TELA) make?

  TELA Bio generated $79.9M in revenue over the trailing twelve months, down 4.49% year over year.

• How do I buy stock in TELA Bio (TELA)?

  TELA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.